Graft vs. Host Disease: Causes, Symptoms, and Treatment Explained

Graft vs. host disease (GVHD) is a unique and sometimes serious complication that can occur after certain types of transplants, especially stem cell or bone marrow transplants. While transplantation can be a life-saving treatment for many conditions, the immune cells from the donor may sometimes recognize the recipient’s body as foreign and begin attacking healthy tissues.

This immune reaction happens because the transplanted donor cells contain immune system components, particularly T cells, that are designed to identify and fight threats. In GVHD, these cells mistakenly target the recipient’s organs, causing inflammation and damage. The condition can range from mild to severe and may affect different parts of the body.

GVHD is generally divided into two main forms: acute GVHD, which often develops within the first few months after transplant, and chronic GVHD, which may appear later and can last for a longer period. The symptoms and severity depend on factors such as the type of transplant, the donor-recipient match, and the person’s overall health.

Common signs of GVHD may include skin changes such as rash or itching, digestive problems like diarrhea or abdominal discomfort, and liver-related issues that can affect overall health. Because symptoms can vary, recognizing early warning signs and receiving timely medical care are important for managing the condition.

Doctors use several approaches to reduce the risk and treat GVHD, including medications that help control the immune response. Treatment plans are personalized based on the severity of symptoms and which organs are affected. Advances in transplant medicine have improved prevention strategies and helped many patients achieve better outcomes.

In this article, we will explore the causes of graft vs. host disease, common symptoms, risk factors, diagnosis, treatment options, and important information about managing this transplant-related complication. Continue reading to learn more about GVHD and how medical care helps support patients after transplantation.

What is Graft vs. Host Disease and Why Does It Occur?

Graft vs. Host Disease is a systemic immunological disorder that occurs when transplanted donor immune cells (the graft) recognize the recipient’s body (the host) as foreign and mount an inflammatory attack against the host’s tissues. This reaction is essentially the reverse of transplant rejection, where the host’s immune system attacks the transplanted organ or cells.

Let’s delve into the intricate workings of the immune system and the nature of allogeneic transplantation. In this type of transplant, the goal is to replace a patient’s faulty or malignant hematopoietic (blood-forming) system with a healthy one from a donor.

However, this process involves transferring not just the stem cells but also mature, functional immune cells, particularly T-lymphocytes, from the donor. These donor T-cells are programmed to identify and eliminate foreign threats, and when they enter the recipient’s body, they begin to survey their new environment.

How Does a Fonated Graft Recognize The Recipient’s Body as Foreign?

A donated graft recognizes the recipient’s body as foreign primarily through differences in cell-surface proteins known as Human Leukocyte Antigens (HLA), which function as the immune system’s unique molecular identification cards. These proteins are present on nearly all cells in the body and allow the immune system to distinguish self from non-self.

When donor T-cells encounter the recipient’s cells, they inspect these HLA markers. If the HLA proteins on the recipient’s cells differ from the HLA patterns the donor T-cells were trained to recognize as self in the donor’s body, they perceive the recipient’s tissues as a foreign threat, initiating a powerful immune response.

More specifically, this recognition process is highly sophisticated. T-cells do not just see the HLA molecules themselves; they recognize a complex formed by the HLA molecule presenting a small piece of a protein (a peptide) from inside the cell. In the context of GvHD, the donor T-cells scrutinize the recipient’s HLA molecules presenting the recipient’s own peptides.

Even with a full match on the major HLA genes (HLA-A, -B, -C, and -DR), subtle differences can still exist in what are called minor histocompatibility antigens. These are different versions of normal body proteins that, when presented by the same HLA molecule, can appear foreign to the donor T-cells. This is why GvHD can still occur even in transplants between HLA-identical siblings.

Once this recognition occurs, the donor T-cells become activated. They begin to multiply rapidly (proliferate) and release a flood of inflammatory signaling molecules called cytokines. This cytokine storm orchestrates a widespread attack, recruiting other immune cells to the site and causing direct damage to the host’s tissues, leading to the clinical signs and symptoms of GvHD.

Types of Transplants Graft vs. Host Disease Typically Happens

Graft vs. Host Disease typically happens as a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), which includes bone marrow, peripheral blood stem cell, and umbilical cord blood transplants. This is the classic setting for GvHD because the very purpose of the transplant is to introduce a new, functional immune system into the recipient.

The transplanted material, or graft, is rich in immunocompetent cells, especially T-lymphocytes, which are the primary drivers of the GvHD reaction. The recipient, having undergone intensive chemotherapy and/or radiation (conditioning regimen) to destroy their own bone marrow and immune system, is left vulnerable and unable to reject the donor cells. This creates a perfect storm where the new, healthy donor immune system can turn against the defenseless host body.

While HSCT is the most common context, GvHD can occasionally occur in other scenarios. One is solid organ transplantation, though it is much rarer. For GvHD to develop after a solid organ transplant, two conditions must be met: the transplanted organ must contain a significant number of viable donor immune cells (lymphocytes), and the recipient must be sufficiently immunosuppressed to be unable to reject those cells.

This is most frequently seen in transplants of organs rich in lymphoid tissue, such as the liver, small bowel, and lung. Liver transplants, for instance, transfer a large population of donor lymphocytes, and if the recipient has a compromised immune system, these cells can engraft and attack.

Another instance is the transfusion of non-irradiated blood products to an immunocompromised patient. The lymphocytes in the transfused blood can mount an attack against the recipient, a condition known as transfusion-associated GvHD (TA-GvHD), which is extremely rare but highly fatal.

Symptoms and Signs of Graft vs. Host Disease

The primary symptoms and signs of Graft vs. Host Disease most commonly affect the skin, liver, and gastrointestinal (GI) tract and are categorized based on their timing and clinical presentation as either acute or chronic GvHD. The manifestation of these symptoms can range from mild and manageable to severe and life-threatening, depending on the grade of the disease and the organs involved.

Next, a closer examination of the specific signs reveals how this systemic immune attack damages different parts of the body. Recognizing these manifestations is critical for prompt diagnosis and the initiation of treatment, as early intervention can significantly mitigate the long-term impact of the disease.

The clinical picture varies not only by the organ system but also by whether the disease process is acute (characterized by rapid, direct inflammatory damage) or chronic (often involving slower, progressive inflammation and fibrosis similar to autoimmune disorders).

Common Signs of GvHD Grouped By Affected Organ

The common signs of GvHD are grouped by the three classic target organs: the skin, presenting with rashes and blistering; the liver, with jaundice and abnormal function tests; and the gastrointestinal tract, causing diarrhea, nausea, and abdominal pain. These organ systems are particularly vulnerable due to their rapid cell turnover and exposure to various antigens, making them primary battlegrounds for the donor immune cells.

Skin is the most frequently affected organ in GvHD. The initial sign is often a maculopapular rash, a rash with both flat, discolored spots (macules) and small, raised bumps (papules). It typically starts on the palms of the hands, soles of the feet, and the head and neck region, then spreads to the trunk and limbs.

It can be itchy and painful. In more severe cases, the rash can evolve into erythroderma (widespread redness of the entire skin surface) or develop blisters (bullae) that can rupture, leading to skin sloughing that resembles a severe burn. The severity is graded based on the percentage of body surface area affected.

Liver GvHD is identified by a rise in liver function tests (LFTs) in the blood, particularly an elevated level of bilirubin. Clinically, this manifests as jaundice, which is a yellowing of the skin and the whites of the eyes (sclera). Patients may also experience pain in the upper right quadrant of the abdomen due to an enlarged liver (hepatomegaly). The damage is caused by donor lymphocytes attacking the small bile ducts within the liver, a condition known as cholestasis, which impairs the flow of bile.

GvHD of the gut can affect both the upper and lower GI tract. Upper GI involvement leads to symptoms like persistent nausea, vomiting, loss of appetite (anorexia), and a feeling of fullness. Lower GI tract involvement is characterized by profuse, watery diarrhea, which can become bloody in severe cases.

This is often accompanied by significant abdominal cramping and pain. The massive fluid loss from diarrhea can lead to severe dehydration, electrolyte imbalances, and malnutrition, making it one of the most dangerous aspects of GvHD.

Symptoms of acute GvHD vs. Chronic GvHD

The symptoms of acute GvHD are characterized by rapid-onset, aggressive inflammation typically occurring within 100 days of transplant, whereas chronic GvHD usually develops later and presents with a broader, more complex array of symptoms resembling autoimmune and fibrotic diseases. This distinction is crucial for diagnosis and treatment, as the underlying pathology and management strategies for each form differ significantly.

Acute GvHD is defined by its classic triad of target organs: the skin, liver, and GI tract. The symptoms are a direct result of cytotoxic T-cell-mediated tissue destruction. The skin rash is inflammatory and can progress rapidly.

The liver involvement leads to cholestatic jaundice. The GI symptoms are marked by high-volume, watery diarrhea due to damage to the intestinal lining. The onset is typically abrupt, and the condition is graded based on the severity of symptoms in these three organs. The underlying mechanism is a direct, alloreactive immune assault.

Chronic GvHD can either evolve from a resolved case of acute GvHD or arise without any prior acute symptoms (de novo). Its onset is generally more insidious and occurs later, often more than 100 days post-transplant. Chronic GvHD can affect virtually any organ system and its symptoms are more diverse, often mimicking autoimmune conditions.

For example, symptoms resemble scleroderma (skin tightening and thickening) or lichen planus (purplish, itchy flat bumps), along with changes in skin pigmentation and hair loss.

Also, sicca syndrome, characterized by severe dryness of the mouth and eyes, is common. The mouth may also have painful ulcers and inflammation. Bronchiolitis obliterans syndrome (BOS) can occur, causing progressive scarring and narrowing of the small airways, leading to shortness of breath and a persistent cough.

Patients may experience joint stiffness and contractures due to inflammation and fibrosis of the connective tissues. Specially, the liver, GI tract, and genitals can also be affected, but the pathology often involves fibrosis (scarring) in addition to inflammation. This makes chronic GvHD a more complex, long-term management challenge.

Causes and Risk Factors for Graft vs. Host Disease

The primary cause of Graft vs. Host Disease is the immunological disparity between the donor and recipient, while key risk factors that amplify this risk include the degree of HLA mismatch, advanced age of the donor or recipient, and the source of the transplanted stem cells. At its core, GvHD is a predictable consequence of introducing an external immune system into a body it does not recognize as its own.

To begin, understanding the interplay between the fundamental cause and the contributing risk factors is essential for predicting, preventing, and managing this complex complication. The entire field of transplantation medicine revolves around minimizing this immunological conflict.

While the central trigger is constant, immune cell recognition of foreignness, the probability and severity of the resulting GvHD are heavily influenced by a specific set of clinical and biological variables that can be assessed before the transplant even takes place.

Primary Trigger for the Immune Reaction in GvHD

The primary trigger for the immune reaction in GvHD is the recognition of mismatched Human Leukocyte Antigens (HLA) and minor histocompatibility antigens on the recipient’s cells by the donor’s T-lymphocytes. This event initiates a complex and destructive cascade of immune activation.

HLA proteins are the gatekeepers of self-recognition, and any perceived difference signals an alarm to the patrolling T-cells of the newly engrafted immune system. The process of GvHD development is often described in a three-step model that clarifies how this initial trigger translates into widespread organ damage.

1. Initial Tissue Damage (Afferent Phase):

The process begins even before the donor cells are infused. The pre-transplant conditioning regimen, which involves high-dose chemotherapy and/or total body irradiation, causes initial damage to host tissues, particularly in the gut, liver, and skin. This damage leads to the release of inflammatory cytokines, such as TNF-α and IL-1, creating a cytokine storm.

These molecules act as danger signals that prime the recipient’s body for a heightened immune response and make the tissues more visible and vulnerable to the incoming donor T-cells.

2. Donor T-Cell Activation and Proliferation (Efferent Phase):

Once the donor stem cell graft is infused, the mature donor T-cells within it encounter the host’s antigen-presenting cells (APCs). These APCs display the host’s HLA and minor histocompatibility antigens.

The donor T-cells recognize these antigens as foreign, leading to their activation, rapid proliferation (clonal expansion), and differentiation into effector cells. This activation is amplified by the pre-existing inflammatory environment created in the first phase.

3. Effector Phase and Tissue Destruction:

In the final phase, the activated donor effector T-cells, along with other recruited immune cells like natural killer (NK) cells and macrophages, migrate to target organs.

They launch a direct cytotoxic attack on the host’s cells and release more inflammatory cytokines, perpetuating a cycle of inflammation and tissue destruction. This cellular and inflammatory assault is what produces the clinical symptoms of GvHD seen in the skin, liver, and GI tract.

Key Risk Factors Increasing The Likelihood of Developing GvHD

The key risk factors that increase the likelihood of developing GvHD are grouped into categories related to the donor-recipient match, patient and donor characteristics, and the specifics of the transplant procedure itself. These factors collectively determine the immunological distance between the graft and the host and the intensity of the potential immune conflict.

For example, histocompatibility mismatch is the single most important risk factor. The risk of GvHD directly correlates with the number of mismatched HLA loci between the donor and recipient.

A transplant from an HLA-identical sibling carries the lowest risk. A transplant from a matched unrelated donor (MUD) has a higher risk, and a mismatched unrelated donor or a haploidentical (half-matched) family member carries the highest risk. Even with a perfect HLA match, differences in these other cell surface proteins can still trigger GvHD.

Additionally, older recipients and older donors are independently associated with a higher risk of both acute and chronic GvHD. This may be due to age-related changes in the immune system and a reduced capacity for tissue repair.

A female donor who has previously been pregnant and is donating to a male recipient increases the risk. During pregnancy, the mother can become sensitized to male-specific minor histocompatibility antigens encoded on the Y chromosome. Her immune cells may later recognize and attack the male recipient’s cells.

The type of graft used has a profound impact. Peripheral blood stem cells (PBSC) contain a much higher number of T-cells compared to bone marrow. Consequently, using PBSC is associated with a faster engraftment but a higher incidence of chronic GvHD. Umbilical cord blood contains naive, immature T-cells and has the lowest risk of causing severe GvHD, but engraftment is slower.

More intensive, myeloablative conditioning regimens cause greater initial tissue damage, leading to a more robust release of inflammatory cytokines and a higher risk of acute GvHD.

Types of Graft vs. Host Disease Treatment and Management

The treatment for both acute and chronic Graft vs. Host Disease is centered on suppressing the overactive donor immune system, with systemic corticosteroids serving as the universal first-line therapy, followed by a range of second-line immunosuppressive agents for resistant cases. The primary goal of treatment is to halt the immune attack on the host’s tissues while preserving the beneficial graft-versus-leukemia (GVL) effect, where the donor cells help eliminate any residual cancer.

Specifically, the management strategy is tailored to the severity of the disease and whether it is acute or chronic. Prophylaxis, or preventative treatment, is also a cornerstone of post-transplant care, with most patients receiving a combination of immunosuppressive drugs starting before the transplant to reduce the initial risk of GvHD. However, once GvHD develops, a more aggressive therapeutic approach is required to bring the immune response under control and prevent irreversible organ damage.

Main Treatment Strategies for Controlling GvHD

The main treatment strategies for controlling GvHD are grouped into first-line, second-line, and targeted therapies, forming a stepwise approach that begins with broad immunosuppression and progresses to more specific immunomodulatory agents if the initial treatment fails. This therapeutic ladder allows clinicians to escalate treatment intensity based on the patient’s response and the severity of the disease.

More specifically, these treatment categories include first-line therapy (corticosteroids). The undisputed standard of care for newly diagnosed acute and chronic GvHD is high-dose systemic corticosteroids, such as methylprednisolone or prednisone.

These powerful anti-inflammatory and immunosuppressive drugs work broadly to inhibit T-cell activation and cytokine production, effectively calming the immune storm. For localized GvHD, such as a mild skin rash, topical steroids may be sufficient. However, for systemic disease affecting internal organs, high intravenous or oral doses are required. About half of patients will respond well to this initial therapy.

Second-line therapies (for steroid-refractory GvHD), patients whose GvHD does not improve or worsens despite adequate steroid treatment are considered steroid-refractory, a condition associated with a poor prognosis. For these individuals, a variety of second-line agents are employed to provide additional immunosuppression.

For targeted and novel therapies, recent advancements have introduced therapies that target specific components of the GvHD pathway, offering new hope for difficult-to-treat cases.

A JAK inhibitor that blocks key inflammatory signaling pathways, it is now an FDA-approved standard second-line treatment for steroid-refractory acute GvHD. Also, a procedure where the patient’s blood is drawn, white blood cells are separated, treated with a photosensitizing agent and exposed to UV light, and then returned to the body. This process is thought to induce immune tolerance and is particularly effective for chronic GvHD affecting the skin and other organs.

Other targeted agents like ibrutinib (for chronic GvHD) and abatacept are also changing the treatment landscape.

Is Graft vs. Host Disease Always Treatable?

Yes, but with significant caveats; while most cases of Graft vs. Host Disease are treatable and can be effectively managed, severe or steroid-refractory forms of the disease can be extremely challenging to control and may lead to irreversible organ damage, long-term disability, or mortality. The success of treatment depends heavily on the severity of the initial presentation, the organs involved, and the patient’s response to first-line therapies.

A majority of patients with GvHD, particularly those with mild to moderate (Grade I-II) acute GvHD, respond well to the standard first-line treatment with corticosteroids. With appropriate management, symptoms can be controlled, and the immune reaction can be suppressed.

Furthermore, the robust GvHD prophylaxis regimens given to almost all allogeneic transplant recipients have significantly reduced the incidence of severe GvHD from the outset. For chronic GvHD, while it may require long-term therapy, many patients can achieve a stable condition and maintain a good quality of life with treatments like low-dose steroids, ECP, or other immunosuppressants.

But, treatment is not always successful as the primary challenge arises in cases of severe, acute GvHD (Grade III-IV) and steroid-refractory GvHD. These conditions are life-threatening. When high-dose steroids fail to control the disease, the prognosis worsens dramatically.

Subsequent lines of therapy have limited success rates and come with their own significant risks, most notably a heightened susceptibility to opportunistic infections due to profound and prolonged immunosuppression. Infection is a leading cause of death in this population.

Chronic GvHD can also be relentless, leading to progressive fibrosis and permanent organ damage (e.g., lung failure from bronchiolitis obliterans) that may not be reversible even if the underlying immune activity is controlled. Therefore, while GvHD is a treatable condition, it remains a formidable and sometimes fatal complication of transplantation.

Graft vs. Host Disease Diagnosis

The official diagnosis of Graft vs. Host Disease (GvHD) is a comprehensive process that relies on a combination of clinical observation, laboratory tests, and, most definitively, histopathological examination of affected tissue. Physicians first assess the patient for characteristic signs and symptoms, which often appear in the skin (rashes, redness, blistering), gastrointestinal tract (nausea, vomiting, diarrhea, abdominal cramps), and liver (jaundice, elevated liver enzymes).

The timing of these symptoms after transplant helps differentiate between acute and chronic forms. While these clinical presentations are strong indicators, they can mimic other post-transplant complications, such as infections or drug toxicities, necessitating further investigation for a conclusive diagnosis.

To support the clinical suspicion, blood tests are performed to evaluate organ function, particularly liver function tests that measure levels of enzymes like bilirubin and alkaline phosphatase. A significant increase in these markers can suggest liver involvement in GvHD. However, the gold standard for confirming GvHD is a biopsy of an affected organ. This procedure involves taking a small tissue sample, most commonly from the skin or gut, which is then examined under a microscope by a pathologist.

The key diagnostic elements physicians look for in a biopsy include evidence of lymphocytic infiltration. The pathologist looks for the presence of donor T-lymphocytes that have infiltrated the host’s tissues.

The examination focuses on identifying characteristic damage caused by this immune attack, such as apoptosis (programmed cell death) in the epithelial cells of the skin or intestinal crypts.

The biopsy also helps rule out other potential causes of the symptoms, such as viral infections (like cytomegalovirus) or adverse reactions to medications, ensuring the correct treatment is administered.

The Difference Between Graft vs. Host Disease and Transplant Rejection

The fundamental difference between Graft vs. Host Disease and transplant rejection lies in the direction of the immune attack, specifically, who is attacking whom.

In GvHD, the immune cells from the donated tissue (the graft) recognize the recipient’s body (the host) as foreign and launch an attack against it. Conversely, in transplant rejection, the recipient’s own immune system (the host) identifies the new organ (the graft) as foreign and attempts to destroy it. This distinction is critical as it dictates the type of transplant involved, the clinical presentation, and the therapeutic approach.

GvHD is almost exclusively a complication of allogeneic hematopoietic stem cell transplantation (HSCT), where a new, complete immune system from a donor is introduced. The mature T-cells within this new graft are the aggressors. In contrast, solid organ transplant rejection, such as a kidney, liver, or heart transplant, is the classic example of the host’s immune system attacking the donated organ.

How to Prevent Graft vs. Host Disease Before a Transplant

Significant measures are taken to prevent, or at least minimize the severity of, Graft vs. Host Disease before and immediately after a transplant. This preventative strategy, known as prophylaxis, is a standard and critical component of the allogeneic stem cell transplant process.

The primary goal of prophylaxis is to suppress the donor T-cells that are responsible for initiating the attack on the recipient’s tissues, without completely eliminating their beneficial graft-versus-leukemia effect, which helps destroy any remaining cancer cells.

One of the most important preventative steps is meticulous donor selection through HLA (Human Leukocyte Antigen) matching. HLA are proteins found on the surface of most cells in the body, and they act as markers for the immune system to recognize self from non-self.

The closer the HLA match between the donor and recipient, the lower the likelihood that the donor T-cells will perceive the recipient’s body as foreign, thereby reducing the risk of severe GvHD. Siblings have the highest chance of being a perfect match, but unrelated donors from registries can also be closely matched.

In addition to HLA matching, the administration of immunosuppressive drugs is a cornerstone of GvHD prevention. These medications are typically started before the transplant and continued for several months afterward.

Long-term Outlook for Patients Who Develop GvHD

The long-term outlook for patients who develop Graft vs. Host Disease is highly variable and depends on a wide range of factors, including the type (acute vs. chronic), severity, organs involved, and the patient’s response to treatment.

While mild cases can be managed effectively with minimal long-term impact, severe or refractory GvHD can lead to significant morbidity, a decreased quality of life, and an increased risk of mortality. A patient’s prognosis is formally assessed using grading and staging systems that quantify the severity of organ involvement.

Acute GvHD that is mild (Grade I), limited to the skin, and responds well to initial steroid treatment generally has a good prognosis. However, severe acute GvHD (Grade III-IV) that involves multiple organs, particularly the gut or liver, is associated with a much poorer outcome and a higher risk of non-relapse mortality.

Chronic GvHD, which can develop months or even years after transplant, presents a different set of challenges. It can manifest similarly to autoimmune diseases, causing issues like skin thickening (sclerosis), dry eyes and mouth (sicca syndrome), joint stiffness, and lung damage (bronchiolitis obliterans).

Managing chronic GvHD often requires long-term immunosuppression, which itself carries risks, such as an increased susceptibility to opportunistic infections and potential organ toxicity. The overall quality of life can be significantly affected, requiring ongoing multidisciplinary care from specialists in dermatology, gastroenterology, pulmonology, and physical therapy.

FAQs

1. What is the survival rate for GVHD?

The survival rate for graft vs. host disease varies widely depending on whether it is acute or chronic, the severity of symptoms, the organs affected, the timing of treatment, and the person’s overall health. Mild cases may respond well to treatment, while severe GVHD involving multiple organs can be more difficult to manage. Advances in transplant care, prevention strategies, and treatments have improved outcomes for many patients.

2. Does GVHD mean the transplant failed?

No, GVHD does not necessarily mean that a transplant has failed. GVHD happens because donor immune cells recognize the recipient’s tissues as different and begin an immune response. In some cases, the activity of donor immune cells can even help fight remaining cancer cells, a benefit known as the graft-versus-tumor effect. However, uncontrolled GVHD can cause complications that require treatment.

3. Which organ has the highest chance of GVHD?

The organs most commonly affected by GVHD include the skin, gastrointestinal tract, and liver. Skin symptoms may include rash, redness, or itching. Digestive symptoms can include diarrhea, abdominal pain, or nausea, while liver involvement may affect liver function. The severity and combination of affected organs can vary from person to person.

4. Can GVHD happen years after transplant?

Yes, chronic GVHD can occur months or even years after a transplant. While acute GVHD usually develops earlier, chronic GVHD may appear later and can cause long-term immune-related problems. Some people may develop symptoms well after the transplant period, which is why ongoing follow-up care is important.

5. Is GVHD terminal?

GVHD is not always terminal. Many people with GVHD improve with treatment, especially when the condition is identified and managed early. However, severe GVHD can become life-threatening, particularly if it causes serious damage to important organs or increases the risk of infections due to weakened immune function.

6. How do you get GVHD?

GVHD occurs after a transplant when immune cells from a donor, usually from a bone marrow or stem cell transplant, attack the recipient’s tissues. The donor cells may see the recipient’s cells as foreign because of genetic differences between the donor and recipient. The risk depends on factors such as donor matching, transplant type, and immune system interactions.

Conclusion

Graft vs. host disease is a complex immune complication that can occur after certain transplants, especially bone marrow or stem cell transplants. It happens when donor immune cells mistakenly attack the recipient’s healthy tissues, leading to inflammation and possible organ damage.

Although GVHD can be serious, it does not always mean a transplant has failed or that recovery is impossible. Many patients respond to treatments that help control the immune reaction and reduce symptoms. Early recognition of warning signs, regular monitoring, and close communication with a healthcare team are important parts of managing GVHD.

Understanding the causes, symptoms, risks, and treatment options for GVHD can help patients and families feel more prepared after transplantation. With continued advances in transplant medicine, prevention and treatment approaches continue to improve outcomes and support better quality of life.

References

• ACDIS – Graft versus host disease
• The University of Texas MD Anderson Cancer Center – Graft vs. host disease: 6 things to know about this stem cell transplant side effect
• Aplastic Anemia and MDS International Foundation – Graft vs. Host Disease (GVHD)
• Blood Cancer United – Graft-versus-host disease (GVHD)
• Memorial Sloan Kettering Cancer Center – Graft-Versus-Host Disease (GVHD)
• CITY OF HOPE – Graft Versus Host Disease (GVHD)
• Anthony Nolan – Graft versus host disease (GvHD)
• Cancer Research UK – What is graft versus host disease (GvHD)?
• Dana-Farber Cancer Institute – Dana-Farber’s Role in the Worldwide Effort to End the Most Common Side Effect of Stem Cell Transplant
• The Regents of The University of California – Graft-Versus-Host Disease (GVHD)